Business
Amarantus Announces $1M Investment
Amarantus Announces $1M Investment.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Announces $1M Investment\n\n\n\n\n\nAmarantus Announces $1M Investment\nPR Newswire\nSAN FRANCISCO, January 27, 2016\n\n\n\nSAN FRANCISCO, January 27, 2016 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $1M investment from an investor introduced to the Company by International Infusion, LLC. The new investment comes in the form of Series H Convertible Preferred Stock and Warrants on the same terms as previously disclosed. As part of the agreement, the Company's 2 largest institutional investors have agreed to certain trading restrictions over the course of the next 7 weeks.\n\nConcurrent with this announcement, the Company has entered into an agreement with International Infusion to provide funding of up to $1.5M over the course of the next five weeks to be used solely for the partial repurchase of Convertible Preferred Stock from Company's 2 largest institutional investors.\n\nThis press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities.\n\nAbout Amarantus BioScience Holdings, Inc. \n\nAmarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of Neurology, Regenerative Medicine and Orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS), an autologous full thickness skin replacement product in development for the treatment of adult severe burns, currently preparing to enter Phase 2 clinical studies. In parallel, the Company is evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas.  ESS has achieved Orphan Drug Designation (ODD) in the area of severe burns, and is seeking ODD status for additional serious dermatologic indications. AMBS also has development rights to eltoprazine, a small molecule currently in clinical development for Parkinson's disease levodopa-induced dyskinesia, an orphan disorder, with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property ...